ON THE EDGE: WHO SHOULD BE GETTING MONOCLONAL ANTIBODIES
We live in a brave new world where Alzheimer’s Disease is a biological diagnosis and disease modifying therapies have become available. However, clinical practice is often not so black and white. How should we manage the ‘worried well’ who think they should be getting mAb therapy but don’t fulfill criteria? How much MCI is enough MCI? Where do logopaenic Alzheimer’s Disease and amyloid positive Posterior Cortical Atrophy fit? This lecture will seek to address this increasingly complex landscape.
